The CNSide® Diagnostics team is excited to announce our participation in the 2026 SNO/ASCO CNS Cancer Conference in Boston, where we will showcase the latest advancements in cerebrospinal fluid (CSF)-based diagnostics for patients & physicians with leptomeningeal...
CNSide is excited to exhibit at the Best of ASCO Austin event, where healthcare professionals can connect, learn, and explore advances in oncology education and diagnostics. This free CME opportunity is a valuable chance to stay current on clinical insights while...
CNSide® Continues Advancing Access to Leptomeningeal Disease and CSF-Based Diagnostics in Neuro-Oncology As the clinical community continues to seek earlier, more accurate methods to diagnose and monitor CNS disease, we look forward to connecting with neuro-onThe...
Visit Our New Proprietary Laboratory Analyses (PLA) CPT Code Supports Reimbursement and Commercial Adoption of CNSide® CNSide® Diagnostics has achieved an important milestone in the advancement of neuro-oncology diagnostics with the assignment of a new American...
Expanded Reimbursement Access for Advanced LM Diagnostics CNSide® Diagnostics continues to expand reimbursement access for clinicians and patients managing suspected leptomeningeal metastases (LM). The CNSide® Cerebrospinal Fluid (CSF) Tumor Cell Enumeration (TCE)...
Advancing CSF-Based Diagnostics in Neuro-Oncology Diagnosing leptomeningeal metastases (LM) remains one of the most complex challenges in neuro-oncology. Because LM involves the spread of cancer to the membranes surrounding the brain and spinal cord, clinicians often...
Advancing Diagnostic Confidence in Leptomeningeal Metastases In leptomeningeal metastases (LM) care, timely and accurate diagnostic information can make a meaningful difference in how physicians evaluate and manage patients with suspected central nervous system (CNS)...
Leptomeningeal metastases (LM) remains one of the most complex and costly complications in oncology. In addition to the significant clinical challenges associated with LM, delayed or uncertain diagnosis can contribute to increased hospitalizations, treatment...
Emerging Health Economics Data Suggest Earlier LM Detection May Reduce Healthcare Costs Leptomeningeal metastases (LM) remains one of the most challenging and resource-intensive complications in oncology, often associated with delayed diagnosis, complex management,...